Sex: F
Vaccine: COVID19, UNK, UNK
Symptoms: Visual acuity tests
Clinical narrative: unilateral conjunctival classic kaposi sarcoma; This is a literature report for the following literature source(s).  The 75-year-old woman presented due to conjunctival lesion in right eye (OD). Her past surgical history included removal of benign adrenal tumour in 1995 and appendectomy in 1969. She had history of benign adrenal tumour, hypertension, hypercholesterolaemia, advanced uveitic glaucoma both eyes (OU), epiretinal membrane OU, pseudophakic bullous keratopathy left eye (OS), pseudophakia OU, chronic iridocyclitis OU, posterior vitreous detachment OU, cystoid macular degeneration OS, presumed ocular histoplasmosis syndrome (POHS) and DED. She also had undergone laser trabeculoplasty OD, bilateral phacoemulsification with posterior chamber intraocular lens (PCIOL), bilateral trabeculectomy, descemet's stripping endothelial keratoplasty OS, capsulotomy OS, seton implant OS and penetrating keratoplasty OS. Her advanced uveitic glaucoma was being treated with latanoprost. She thereafter started receiving topical ciclosporin [cyclosporin] drop and topical loteprednol-etabonate [loteprednol] drop, OU, for DED. She was immunised with booster dose of tozinameran [Pfizer COVID vaccine], prior to the current presentation. However, after several weeks of tozinameran immunisation, she complained of red and irritated conjunctival area in OD, described as bubbling. Her uncorrected vision was 20/20-2 OD and LP OS, and the applanation intraocular pressure (IOP) was at 11 mmHg OU. She had a diffuse avascular bleb in the superior quadrant, and the anterior segment examination revealed an elevated nodular and plaque-like conjunctival lesions OD along with some bleb area involvement. The eye ultrasound revealed thickened conjunctival lesions OD with the largest lesion of 1.68mm height. The histopathology examination was consistent with KS. Based on these findings, unilateral conjunctival classic KS secondary to tozinameran, ciclosporin and loteprednol-etabonate was considered. The woman started receiving topical interferon-alpha-2b 1000000 units/mL 4 times/day for 6 weeks, for conjunctival lesion. Despite interferon-alpha-2b, the size of conjunctival lesions from the initial presentation failed to decrease/regress; indicating treatment failure with interferon-alpha-2b. Her uncorrected acuity remained at 20/20 OD. Thus, she was treated with electron therapy, leading to slow improvement for the next 3 months. Later, she remained disease-free with no KS recurrence. The authors hypothesize that tozinameran vaccination and the local immunosuppression caused by topical loteprednol-etabonate and ciclosporin were the major co-factors needed to induce the localized conjunctival KS in this case. However, topical interferon-alpha-2b therapy failed to decrease the size of the conjunctival lesions.  No follow-up attempts are possible.; Sender's Comments: The event Kaposi's sarcoma is conservatively assessed as related to the suspect drug BNT162B2 based on close temporal association but consider also possible contributory effects from medical history of the patient and/or concomitant medications. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.